Through collaborations with Bayer, Novo Nordisk, Evotec, and Mitsubishi Tanabe Pharma Corporation, Dewpoint pushes the boundaries to accelerate the translation of condensate biology into medicine for ...
Late-stage trial in Alzheimer's opens 10 sites in US, with results due in 2025 and 2026 Appoints US-based Chief Commercial ...
Dewpoint Therapeutics Inc. and Mitsubishi Tanabe Pharma Corp. have entered a research collaboration worth up to $480 million ...
Sanofi unveiled a plan to build a $1 billion manufacturing site in Beijing while completing construction at a plant in ...
6d
Amarillo Biosciences (OTCMKTS:AMAR) recently entered into a Memorandum of Understanding (MOU) with Taiwan Tanabe Seiyaku Co., Ltd., a corporation majority-owned by Mitsubishi Tanabe Pharma Corporation ...
Dewpoint Therapeutics CEO Ameet Nathwani stated: “This partnership underscores the transformative potential of our small ...
As part of the deal, Dewpoint can expect an undisclosed upfront payment from Mitsubishi Tanabe Pharma Corporation (MTPC) in ...
Privately-held Dewpoint Therapeutics, a Boston, USA, biotech developing therapeutics by targeting biomolecular condensates, ...
Shares of US precision medicines firm Relay Therapeutics closed down 6% at $4.39 yesterday after announced a licensing deal ...
Mitsubishi Tanabe Pharma is offering Dewpoint Therapeutics up to $480 million biobucks in a new research pact centering ...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of two abstracts on investigational ND0612 in Parkinson's disease (PD) at the 2024 Annual Meeting of the Parkinson Study ...
Addressing unmet medical needs: Sjogren's syndrome is a chronic autoimmune disease affecting exocrine glands, with no curative treatments currently available. Global prevalence estimates vary from 0.1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback